SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway: SREBP2 Inhibitor sensitizes HCC to lenvatinib

Lenvatinib has become the first-line therapy in advanced hepatocellular carcinoma (HCC), but its efficacy is still limited because of the inevitable development of resistance. It has been reported that cellular cholesterol levels are associated with tyrosine kinase inhibitor (TKI) efficacy. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Minghao, Chen, Zhenmei, Shao, Weiqing, Chen, Yiran, Lin, Zhifei, Yi, Chenhe, Li, Yitong, Lu, Lu, Zhou, Yu, Lin, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520477/
https://www.ncbi.nlm.nih.gov/pubmed/37434430
http://dx.doi.org/10.3724/abbs.2023122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520477/
https://www.ncbi.nlm.nih.gov/pubmed/37434430
http://dx.doi.org/10.3724/abbs.2023122

Ejemplares similares